Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs

The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.

We haven't written up this one. CNBC World has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at cnbc.com →

More in Finance & Markets

More from Monday 21 September →